Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Camiglibose. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 9/20 | 0.49 |
| ▸ | MGAM | O43451 | 8/20 | 0.49 |
| ▸ | SI | P14410 | 3/20 | 0.45 |
| ▸ | GBA1 | P04062 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | LCT | P09848 | 1/20 | 0.45 |
| ▸ | GBA2 | Q9HCG7 | 7/20 | 0.44 |
| ▸ | UGCG | Q16739 | 3/20 | 0.44 |
| ▸ | AGL | P35573 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Camiglibose SCHEMBL3952283 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL5238483 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL2052995 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL1201508 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL4604473 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL758524 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL5186895 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL614436 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL6794338 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 | |
| Camiglibose SCHEMBL19510347 | 0.99 | GAA (0.50) | GAAMGAMSIGBA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 4016 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20250134923-A1 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | JUNION LABS PTE. LTD. (SG) | 2025-05-01 | — | — | US | claimed |
| EP-4392044-A2 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | Junion Labs Pte. Ltd. (SG) | 2024-07-03 | — | — | EP | claimed |
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2023-10-12 | — | — | US | claimed |
| WO-2023038575-A2 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | JUNION LABS PTE. LTD. (SG) | 2023-03-16 | — | — | WO | claimed |
| CN-109832425-A | Tilapia mossambica forms mid-term vitamin premix and preparation method | 浙江海洋大学 | 2019-06-04 | — | — | CN | claimed |
| US-10294225-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2019-05-21 | — | — | US | claimed |
| CN-109717050-A | A kind of culture substrate of cinnamomum camphora | 海盐森植生物科技有限公司 | 2019-05-07 | — | — | CN | claimed |
| US-20180162858-A1 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS | PFIZER INC. (US) | 2018-06-14 | — | — | US | claimed |
| US-9908883-B2 | N1-pyrazolospiroketone acetyl-CoA carboxylase inhibitors | PFIZER INC. (US) | 2018-03-06 | — | — | US | claimed |
| WO-2001082916-A2 | COMBINATION THERAPEUTIC COMPOSITIONS AND METHODS OF USE | TULARIK INC. (US) | 2001-11-08 | — | — | WO | claimed |
| EP-1145717-A2 | Synergistic effect of a sulfonylurea and/or non-sulfonylurea K plus ATP channel blocker, and a phosphodiesterase 3 type inhibitor | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| EP-1136071-A2 | Use of glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-09-26 | — | — | EP | claimed |
| WO-2001047468-A2 | ASSOCIATION OF DEOXYFRUCTOSAZINE AND AN ANTIDIABETIC INHIBITING ALPHA-GLUCOSIDASE | AVENTIS PHARMA S.A. (FR) | 2001-07-05 | — | — | WO | claimed |
| CN-1300223-A | Disposable absorbent article having a skin care composition containing an enzyme inhibitor | PROCTER & GAMBLE (US) | 2001-06-20 | — | — | CN | claimed |
| EP-1088824-A2 | Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors | Pfizer Products Inc. (US) | 2001-04-04 | — | — | EP | claimed |
| EP-1061962-A1 | DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-27 | — | — | EP | claimed |
| EP-0638317-B1 | Pharmaceutical composition comprising glucosidase- and/or amylaseinhibitors, and a lipase inhibiting agent | HOFFMANN LA ROCHE (CH) | 2000-03-15 | — | — | EP | claimed |
| WO-1999045973-A1 | DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | claimed |
| EP-0638317-A1 | Pharmaceutical composition | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-15 | — | — | EP | claimed |